Literature DB >> 24409956

From HTS to Phase I: the Institute for Therapeutics Discovery and Development at the University of Minnesota.

Peter I Dosa, Gunda I Georg, Vadim J Gurvich, Jon E Hawkinson, Michael A Walters, Henry L Wong1.   

Abstract

The high-throughput screening core at the University of Minnesota is part of the Institute for Therapeutics Discovery and Development (ITDD), a comprehensive drug discovery and development center. The Institute provides scientific services to both academic and business communities and supports translational medicine via collaborations and contractual work. The ITDD is well-known for its broad range of screening capabilities and offers extensive medicinal chemistry expertise along with GMP scale-up and pre-clinical pharmacology support.

Entities:  

Mesh:

Year:  2014        PMID: 24409956     DOI: 10.2174/1386207317666140109122033

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  3 in total

Review 1.  Mitigating risk in academic preclinical drug discovery.

Authors:  Jayme L Dahlin; James Inglese; Michael A Walters
Journal:  Nat Rev Drug Discov       Date:  2015-04       Impact factor: 84.694

2.  A Curiously Linear Path to Academic Drug Discovery.

Authors:  Kathryn M Nelson
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

Review 3.  The essential roles of chemistry in high-throughput screening triage.

Authors:  Jayme L Dahlin; Michael A Walters
Journal:  Future Med Chem       Date:  2014-07       Impact factor: 3.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.